Resolving heterogeneity in Diffuse Large B-cell Lymphoma 1 using a comprehensive modular expression map 2

- 3
- Matthew A. Care^{1,2*}, Daniel Painter¹, Sharon Barrans³, Chulin Sha⁴, Peter Johnson⁵, Andy 4 Davies⁵, Ming-Qing Du⁶, Simon Crouch¹, Alex Smith^{1,2}, Eve Roman^{1,2}, Cathy Burton^{3,2}, Gina 5
- Doody^{2,7}, David Westhead^{2,8}, Ulf Klein2^{2,7}, Daniel J. Hodson⁹, Reuben Tooze^{2,3,7*} 6
- 7
- 8 ¹Epidemiology and Cancer Statistics Group, Department of Health Sciences, University of
- 9 York, York YO10 5DD, UK;
- ²National Institute of Health Research Leeds Biomedical Research Centre 10
- 11 ³Haematological Malignancy Diagnostic Service, St. James's Institute of Oncology, Leeds LS9
- 12 7TF, UK;
- 13 ⁴Institute of Basic Medicine and Cancer of Chinese Academy of Sciences, Economic
- Technology Dev Zone, Hangzhou, 310000, Zhejiang province, China; 14
- ⁵University of Southampton, Southampton SO16 6YD, UK; 15

⁶Division of Cellular and Molecular Pathology, Department of Pathology, University of 16

- 17 Cambridge, Cambridge CB2 0QQ, UK;
- ⁷Division of Haematology and Immunology, Leeds Institute of Medical Research, University 18
- 19 of Leeds, Leeds, LS9 7TF, UK;
- 20 ⁸Bioinformatics Group, School of Molecular and Cellular Biology, University of Leeds, Leeds
- 21 LS2 9JT, UK;
- ⁹Wellcome-MRC Cambridge Stem Cell Institute, University of Cambridge, Puddicombe Way, 22
- 23 Cambridge CB2 0AW, UK;
- 24 Correspondence to:
- 25 *Reuben Tooze e-mail: r.tooze@leeds.ac.uk
- 26 *Matthew Care e-mail: m.a.care@leeds.ac.uk
- 27 Lead contact: Reuben Tooze, Wellcome Trust Brenner Building, Leeds Institute of Medical
- 28 Research, University of Leeds, Leeds, LS9 7TF, UK, tel: (44)-113-3438639, e-mail:
- 29 r.tooze@leeds.ac.uk
- 30

31 Abstract

32 Diffuse large B-cell lymphoma (DLBCL) is characterised by pronounced genetic and biological 33 heterogeneity. Several partially overlapping classification systems exist – developed from 34 mutation, rearrangement or gene expression data. We apply a customised network analysis 35 to nearly five thousand DLBCL cases to identify and quantify modules indicative of tumour 36 biology. We demonstrate that network-level patterns of gene co-expression can enhance 37 the separation of DLBCL cases. This allows the resolution of communities of related cases 38 which correlate with genetic mutation and rearrangement status, supporting and extending existing concepts of disease biology and delivering insight into relationships between 39 40 differentiation state, genetic subtypes, rearrangement status and response to therapeutic 41 intervention. We demonstrate how the resulting fine-grained resolution of expression states 42 is critical to accurately identify potential responses to treatment. 43

Significance statement: We demonstrate how exploiting data integration and network analysis of gene expression can enhance the segregation of diffuse large B-cell lymphoma, resolving pattens of disease biology and demonstrating how the resolution of heterogeneity can enhance the understanding of treatment response.

49 Introduction

50 Heterogeneity is a characteristic feature of diffuse large B-cell lymphomas (DLBCL). Consistent subtypes have been resolved based on expression state, mutational profiles and 51 52 cytogenetic features. Amongst the most significant insights has been the association of DLBCL with either germinal centre (GCB) or post-germinal centre/activated B-cell (ABC) 53 counterparts.¹ More recently analysis of mutation patterns in DLBCL have converged onto 54 recurrent patterns of co-mutation that can be used to define genomic subtypes.²⁻⁷ A third 55 56 approach widely used in clinical practice is separation by gene rearrangement status with 57 identification of high-risk DLBCL cases based on double-hit (DH) or triple-hit (TH) rearrangements of MYC and BCL2 and/or BCL6 genes.⁸⁻¹¹ 58

Expression-based classification of DLBCL is not restricted to identification of cell-of-origin 59 60 (COO) classes, with the parallel consensus cluster classification (CCC) focusing on metabolic, signalling and host response features.¹² The latter have also been identified in separate 61 stromal survival predictors.¹³ Furthermore, high-risk DLBCL cases have been identified based 62 on gene expression features, learned either from patterns in Burkitt lymphoma.¹⁴ or based 63 on direct similarity to cases with *MYC* and *BCL2* DH.¹⁵ These approaches identify overlapping 64 sets of cases and are enriched amongst DLBCL associated with mutations of EZH2 and 65 BCL2.^{2,4,5} 66

67 Single-cell expression analysis of germinal centre (GC) B-cells has provided additional 68 insight, separating features of the two main functional populations of dark and light zones, 69 in which B-cells undergo proliferation, somatic hypermutation and T-cell mediated 70 selection, along with intermediate populations including those transitioning to post-GC differentiation.¹⁶⁻²¹ Additionally, the calculated contributions of multiple cell states, 71 72 including both neoplastic B-cells and accompanying host response has been used to assign DLBCL to ecotypes;²² and functional expression signatures have been used to define 73 74 differences in lymphoma microenvironments across both conventional COO classes and genomic DLBCL categories.²³ However, an integrated picture unifying features of expression, 75 76 mutation and rearrangement status is still developing. Here we address this issue using an 77 approach which resolves the intrinsic structure of gene co-expression. Drawing on a broadly representative resource of close to 5000 DLBCL cases across prior studies, we demonstrate 78

- 79 how the resultant integrated view of DLBCL expression biology enhances the informed
- 80 selection of features for expression-based classification.
- 81

82 **Results**

83 An integrated gene expression context for DLBCL

84 To provide a comprehensive exploration of DLBCL biology from the perspective of gene 85 expression we employed parsimonious gene correlation network analysis (PGCNA) (Supplemental Figure 1).²⁴ This approach allows integration of multiple datasets across 86 platforms and makes use of radical edge reduction to efficiently derive the configuration of 87 large networks and optimize modularity.^{24,25} In this approach the focus for each gene is on 88 the mostly highly correlated gene partners, hub nodes/genes in the network emerge 89 90 consequent to being highly correlated partners of many other genes and the primary 91 determinant of resolved modules is the pattern and consistency of gene co-expression in 92 DLBCL data.

We utilised a broadly representative sample of available DLBCL datasets divided into two components. For network discovery we used gene expression derived from 14 DLBCL datasets, restricting to datasets with >50 DLBCL cases, encompassing a total of 2,505 cases.^{2,12,13,26-35} The resulting network reflects a representative sample of DLBCL expression data from multiple sources, mitigating against biases linked to case selection and platform features. Recent datasets that combine mutation and expression features, totalling 2,484 cases, were reserved for downstream analysis.^{3,5,14,36,37}

100 The resulting DLBCL expression network resolved into 28 modules of gene co-expression, 101 across 16,054 genes/nodes (Figure 1a, <u>https://mcare.link/DLBCL2</u>, Supplemental Table 1). A 102 comprehensive gene ontology and signature enrichment was used to assess biological 103 features associated with these modules. Representative terms were selected to identify 104 notable expression patterns associated with each module (Figure 1b, Supplemental Figure 2, 105 Supplemental Table 2).

Several features were evident. Classifier genes used for separation of ABC and GCB classes in the original COO classifier divided discretely and exclusively between two modules: M9 containing all GCB classifier genes, and M11 containing all ABC classifier genes (M11 ABC: pvalue 6.95x10⁻¹⁹ and M9 GCB: 1.57x10⁻¹¹).³⁸ These two modules also capture the majority of

110 B-cell lineage gene expression as assessed by signature enrichment (e.g. SignatureDB pan-B 111 or Resting Blood B-cell). Thus, the fundamental separation of GCB- and ABC-related 112 expression patterns was rediscovered as a primary feature of gene co-expression patterns in the network structure. The more numerous CCC genes divided across several modules but 113 with significant enrichments in specific modules (M9:B-cell receptor p-value 3.27x10⁻⁵⁷, 114 M3:Host response p-value 1.64x10⁻⁶⁴ and M13:Oxphos p-value 1.38x10⁻⁰⁵).¹² Additional 115 116 modules separated features related to MYC function (M8), cell cycle (M7), glycolysis (M13), 117 and sterol biosynthesis (M19). Host response/microenvironment was divided between 118 modules related to stromal/angiogenesis (M4), T/NK-cells (M10), monocytes/macrophages 119 (M3) and IFN responses (M20). Highly co-ordinated gene batteries were resolved for 120 nucleosome components (M18), homeobox (M23), immediate early (M26) and 121 metallothionein genes (M25). Several modules related to structural chromosomal regions 122 including chr6 (M16), chr7 (M14), chr17p (M17), chrX (M13) and chrY (M24).

The network thus provides an integrated picture of gene expression in DLBCL encompassing details of lineage-specific gene expression set against a diverse backdrop of cell biology and microenvironment and resolving fine-grained patterns of gene co-expression. These are available as an extensive online resource covering gene correlation data, interactive network visualisations and downstream comparisons (https://mcare.link/DLBCL2).

128

129 Meta-hazard ratio analysis confirms associations between biology and outcome

130 A meta-hazard ratio analysis merging overall survival data from training datasets can 131 illustrate the association of module and individual gene expression with outcome across the 132 entire network. We limited analysis to cases treated with R-CHOP immunochemotherapy. 133 The result included the segregation of good and adverse outcome between component 134 genes of the GCB (M9) and ABC (M11) modules (Figure 1c and d), as well as adverse 135 outcome with Mitochondrial and MYC overexpression module (M8) and Ribosome module (M7) and good outcome linked to expression of the Stromal/Angiogenesis module (M4) 136 which encompasses features of known survival predictors.¹³ 137

138

139 **Resolving detailed differentiation states in GCB and ABC modules**

140 Biological detail can be resolved at different levels of granularity in the network. An iterative 141 analysis of gene correlation within modules can resolve the most highly related gene

142 neighbourhoods, and the extent to which underlying information is successfully separated

143 by such neighbourhoods can be assessed with gene signature enrichment.²⁴

144 Assessed systematically across the network, the ABC and GCB modules were amongst those 145 with highest neighbourhood-level information content (Supplemental Figure 3, Supplemental Table 3 and 4). Given the central importance of B-cell differentiation to 146 lymphomagenesis,^{39,40} we focused on the relationships of the GCB and ABC 147 148 neighbourhoods in more detail (Figure 2a and b, and https://mcare.link/DLBCL2). The GCB 149 module (M9) resolved into 16 neighbourhoods (Figure 2b and c, Supplemental Table 4). 150 These included neighbourhoods enriched for different GC B-cell subsets - LZ (M9 n2 and n6), DZ (M9 n5 and n15), CD40/NFκB responses linked to LZ B-cells (M9 n10), 151 152 Intermediate-e/CCR6 memory B-cell precursor (M9 n3 and n4) and pre-memory/memory 153 B-cells (M9 n14).¹⁶ A similar informative separation was observed for the ABC module 154 which divided into 17 neighbourhoods (Figure 2b and d, Supplemental Table 4). This 155 separated expression related to CCR6+ memory B-cell precursors (M11 n5), pre-memory B-156 cells (M11 n5 and n7), and plasmablast/plasma cell (M11 n6). These cell state associations 157 overlapped with targets of key transcriptional regulators IRF4 (M11 n1, n6 and n7), BLIMP1 158 (M11 n7) XBP1 (M11 n6), and NFκB-response genes specific to the ABC modules (M11 n4 159 and n8).

160 The COO gene expression classifier established the paradigm for the successful application 161 of small numbers of representative genes to separate individual DLBCL cases into distinct expression states.³⁸ Genes that have a high degree of connectivity in the network may 162 163 provide particularly useful information to summarise expression states of many correlated 164 neighbours and overlapping information can be derived from different but correlated genes 165 within network neighbourhoods/modules. The latter illustrates how different classifier gene 166 sets can be selected to arrive at broadly similar answers for a given expression state. Many 167 of the COO classifier genes emerged as hub nodes within the respective GCB and ABC neighbourhoods (Figure 2a). Considering the genes used in the original COO classifier, those 168 169 used to classify GCB-DLBCL were all contained within the M9 module and segregated 170 primarily between two neighbourhoods M9 n3 (BCL6, MME (CD10) and SERPINA9) and 171 M9 n4 (DENND3, ITPKB, LMO2 and NEK6) while IRAG2 (LRMP) belonged to M9 n11. The 172 COO ABC-classifier genes were distributed across 5 neighbourhoods in module M11 173 (M11 n1, n2, n3, n4 and n7), illustrating that these genes sample multiple aspects of the

ABC network module (Figure 2a and Supplemental Figure 3c). We conclude that neighbourhood-level patterns of gene expression can resolve details of biology related to differentiation state and can illustrate the inter-relationship of individual genes used in targeted expression-based classifiers.

178

179 Network gene expression patterns show consistent association with mutation state

180 HMRN, REMoDL-B and Reddy datasets include both gene expression and mutation data.^{5,36,37} These studies were not used in network generation. We could therefore test 181 182 whether patterns of gene co-expression in the network correlated with mutations in these 183 independent datasets. Since many mutations in DLBCL are rare we considered both the 184 correlation of expression and mutation within individual datasets and as a consensus meta-185 mutation correlation across the three datasets. We summarised module- or neighbourhood-186 level gene expression as metagenes (module or neighbourhood expression values, MEV or 187 NEV) and assessed the correlation of these values with the presence or absence of gene 188 mutation, reducing mutation data for each case into a mutated/unmutated binary call for 189 each gene with annotated putative pathogenic mutations.

190 Metagene expression patterns were significantly associated with mutation state (Figure 3 191 and Supplemental Figure 4). At module level the primary separation was into two clusters 192 corresponding to M9 GCB and M11 ABC mutation correlations. M9 GCB correlated 193 significantly with a wide range of mutations consistent with known associations both of COO-defined GCB-DLBCL and follicular lymphoma (FL),^{3,41} and anticorrelated with the 194 primary mutations linked to COO-defined ABC-DLBCL. M11 ABC exhibited the reciprocal 195 196 anticorrelation with mutations linked to COO-defined GCB-DLBCL and positive correlation 197 with mutations characteristic of COO-defined ABC-DLBCL. Modules which shared mutation 198 correlations with M9 GCB included: M13 ChrXGlycolysis, M23 Homeobox, M28 ITGB8, 199 M6 ZincFinger, M6 Chr6; while modules with shared mutation correlations with M11 ABC 200 included: M8 MitochondrionMYC, M18 Nucleosome, M7 CellCyle and M17 Chr17p. An 201 additional cluster of modules focused on shared correlations with CDKN2A mutation 202 including M14 Chr7 and M15 Ribosome.

Further subdivision was evident when modules were considered at neighbourhood-level. For instance, while most neighbourhoods in the GCB module (Figure 3 top left panel) shared correlation with a core set of gene mutations including *EZH2*, *BCL2* and *CREBBP* the 206 neighbourhood-level analysis could discriminate heterogeneity for other genes. For 207 example, neighbourhoods discretely separated between those with SOCS1, NFKBIA, SGK1, 208 IRF8, TNFRSF14, S1PR2, CD83, STAT6 mutation association and those with MYC, CDKN2A 209 mutation association. Additionally, mutation in several genes including BTG2, DDX3X, 210 FOXO1, RHOA, PAX5 or STAT6 Y419 hotspot mutations associated with select patterns of 211 GCB neighbourhood expression. Similarly, in the ABC module (Figure 3 top right panel) most 212 neighbourhoods shared association with a common set of mutated genes including MYD88, 213 CD79B, PIM1, ETV6, TBL1XR1, BTG2, PRDM1. However, more selective associations were 214 evident for BCL10, IRF4, CDKN2A, NOTCH2, TMEM30A. Other M11 ABC neighbourhoods 215 captured guite distinct mutation associations lacking positive correlation with the MYD88, 216 CD79B mutation cluster and showing associations with NFKBIA, SOCS1, SGK1, BTG1 or with 217 *BCL2* mutation and features transitional to a GCB-like pattern.

218 Further examples of informative separation at neighbourhood-level are illustrated by the 219 M3 ImmuneResponseMonocyteEnriched and M7 CellCycle neighbourhoods. For the 220 M3 ImmuneResponseMonocyteEnriched module (Figure 3 bottom left panel) common 221 association was observed for mutation in CD58. However, select neighbourhoods (M3 n6, 222 M3 n8 and M3 n11) were also associated with mutation in either TET2 or DNMT3A. For the 223 M7 CellCycle module (Figure 3 bottom right panel), TP53 mutation, was significantly 224 associated with 12/15 of neighbourhoods which contrasted with its lack of significant 225 association with any M8 GCB or M11 ABC neighbourhoods. Interestingly, 8/12 226 neighbourhoods linked to TP53 mutation also share association with mutation of TMEM30A, 227 recently identified as a tumour suppressor inactivated in DLBCL, but in contrast to TP53 228 linked to a favourable response to R-CHOP therapy.⁴² Multiple M7 CellCycle 229 neighbourhoods shared association with mutation of genes such as MYD88, CD79B, PIM1, 230 ETV6 characteristically linked to the ABC-state, while from the perspective of GCB-linked 231 associations select M7 CellCycle neighbourhoods were associated with mutation in MYC 232 and DDX3X.

While this analysis is limited to the sets of genes tested in targeted mutation panels, the most important known mutational features of DLBCL are included. The results identify distinct and significant associations of network derived gene co-expression patterns with driver mutations and argue that the granularity provided by the network at module and neighbourhood-level is informative of underlying tumour biology.

238

239 Network-level gene expression patterns enhance consistent segregation of DLBCL

240 Given the consistent association between modules/neighbourhoods and mutation state we 241 reasoned that network-level information may contribute to enhanced expression-based 242 segregation of DLBCL cases. To evaluate this, we tested how recurrently discoverable the 243 co-segregation of DLBCL cases was with different selections of features and different 244 clustering methods. To select informative features for clustering we split all modules into 245 neighbourhoods and considered features either at the level of individual genes or collapsing 246 genes within neighbourhoods or modules into single values (MEV/NEVs). We then selected 247 the most informative features at either gene, NEV or MEV level using several different 248 approaches. The selected features were then used to cluster the DLBCL datasets (n=16, see Supplemental Table 1, DatasetInfo) using either PGCNA or consensus clustering (CC).⁴³ The 249 250 resultant clusterings were compared based on the extent of recurrently discoverable co-251 segregation of DLBCL cases. In total 33 attribute sets were examined (see Supplemental 252 Table 5). This showed (Figure 4a): i) that selections based on PGCNA network modules with 253 edge information (Net+Strct) outperformed ranking without edge information (Network); ii) 254 that having only M9/M11 at neighbourhood-level (NEV M9M11) outperformed selections 255 using all neighbourhoods; iii) that collapsing genes per module/neighbourhood to 256 MEV/NEVs outperformed gene-level clusterings; and iv) that using network structure and 257 edge information (Net+Strct) to inform gene choice and collapsing genes to 258 module/neighbourhood values (MEV/NEVs) significantly outperformed gene selection based 259 on most variant expression (Top1000/5000). We conclude from this that use of network 260 information can enhance the selection of attributes for consistent clustering of DLBCL cases.

261

262 Network information resolves communities of lymphoma cases with shared biology

A common feature of classification based on multiple parameters is the identification of consensus cases on which various classification tools can agree when using the same features for classification, and edge cases where the classification is more ambiguous.⁴⁴ Therefore, extending the concept of consensus or ensemble clustering,^{12,45} we focused on cases co-clustered by both CC and PGCNA methods. This identified 12 ensemble case clusters (Figure 4b), which we refer to as Lymphoma Communities (LCs). These cases were then used as a reference set to train a machine learning tool. The machine learning tool was

used to reclassify all cases in the HMRN (Figure 4b) and other datasets (see Supplemental
Methods for details). A similar distribution of cases falling into these communities was
recovered across a range of datasets (Figure 4c and Supplemental Figure 5 & 6). These
communities were named according to patterns of module expression or associated
pathological/molecular features that were identified in downstream analyses.

275 Amongst the 12 LCs (Figure 4b, Supplemental Figure 6) two communities identified cases 276 dominated by ABC module gene expression which were distinguished by differences in 277 immune response-related features as immune response poor (IcABC) or immune rich (IcABC-278 **IR**). Cases with plasmablastic features (IcPBL) were distinguished by expression of XBP1 279 targets and cancer testis antigens. A distinct subset of cases with ABC-related features 280 shared the expression of cancer testis antigens (IcCT). Amongst cases with weak B-cell 281 patterns, two communities were dominated by immune response modules (IcIR and IcIR-282 **TET2** - distinguished by *TET2* mutation enrichment, see below). Six communities were 283 characterised by expression of multiple GCB-related neighbourhoods. These included a 284 community with GCB features and distinct stromal/EMT-related gene expression (LGCB-285 EMT) and a community with mixed GCB and ABC expression features along with cell cycle, 286 MYC, and sterol biosynthesis modules, suggestive of transition from GCB to an ABC/post-GC 287 state (cGCB-Xit, Supplemental Figure 6). Similar proliferation and growth-related module 288 expression were combined with polarised high GC DZ and low GC LZ neighbourhood 289 expression, along with low CD40/NF κ B and MHC-II genes in a GCB DZ-like community 290 (lcGCB-DZ). The remaining three GCB communities were distinguished by different patterns 291 of GCB neighbourhood expression, wider network features and other associations in 292 downstream analyses (lcGCB - most canonical GCB-like, lcGCB-FL - underlying FL diagnosis, 293 **GCB-SOCS1** – selective SOCS1 mutation association).

294 The combination of overview and gene-level granularity provided by the network afforded a 295 further means to assess relationships between the resolved communities across all network 296 genes or those specific to the GCB/ABC differentiation state (Supplemental Figure 7 and 8). 297 This is exemplified at the level of GCB and ABC neighbourhood genes, where the _{In}GCB-Xit 298 community straddles both key GCB and ABC features and contrasts with the more discrete 299 patterns of other communities such as $_{lc}$ GCB-DZ and $_{lc}$ ABC (Supplemental Figure 7). At the 300 whole network level, wider differences in gene expression within modules are further 301 illustrated as seen for the comparison between IcGCB-FL and IcGCB (Supplemental Figure 8).

302 Thus the 12 DLBCL LCs reinforced the significance of segregation into ABC and GCB 303 expression patterns while distinguishing heterogeneity within these broad categories.

304

305 **DLBCL communities link to mutation patterns**

306 An important test of the DLBCL LCs was whether these also showed significant association 307 with mutation state. To address this we analysed the enrichment of mutations in DLBCL 308 communities by integrating enrichment p-values derived across the individual HMRN, REMoDL-B and Reddy datasets.^{5,36,37} At a p-value threshold <0.01 (in \geq 2 datasets) the 309 310 communities showed significant and distinct associations with mutation patterns. These 311 separated in concordance with the expression states between mutational features linked to 312 ABC, GCB, and host/immune response characteristics (Figure 5a). Thus, IcABC and IcABC-IR 313 shared association with MYD88, CD79B, PIM1, PRDM1, CDKN2A and differed in association 314 of with ETV6, TBL1XR1 and IRF4 mutations. The ABC-related IcCT community was selectively 315 enriched for MYD88 and PIM1 mutations and was additionally enriched for BCL10, TP53, 316 *MEF2B* mutations. These patterns separated most distinctly from _{Ic}GCB and _{Ic}GCB-DZ. These 317 shared enrichment for BCL2, EZH2, DDX3X, IRF8, PTEN, TNFRSF14, GNA13 mutation. GCB-DZ 318 was additionally enriched for CREBBP, KMT2D, BTK, POU2F2, S1PR2, FOXO1, MYC, MEF2B 319 mutation, while IcGCB was enriched for CARD11, B2M, EBF1, MSH6, RHOA, TET2, SGK1 320 mutation. IcGCB-FL shared association with CREBBP, KMT2D, TNFRSF14 but was 321 distinguished by association with STAT6 mutations including significant enrichment of the 322 STAT6 Y419 hotspot mutation. IcGCB-EMT shared enrichment of SGK1 and TNFRSF14 with 323 IcGCB but otherwise lacked distinct associations. IcGCB-SOCS1 and IcGCB-Xit differed from 324 other GCB-related expression groups. IcGCB-SOCS1 associated with SOCS1, NFKBIA, SGK1, 325 BTG1, GNA13, CD83, NFKBIE, ZFP36L1 and STAT6 but not the STAT6 Y419 mutation hotspot, 326 while IcGCB-Xit showed a further distinctive pattern with selective enrichment for CD70, 327 CCND3, BTG2 mutations. While IcIR only displayed anti-correlations with mutation state 328 likely reflecting the diluting effect of host response components, IrIR-TET2 cases were 329 selectively associated with TET2 mutations.

The observed associations between LCs and mutations resembled the patterns in recent mutation-based classifications of DLBCL. We therefore assessed the relationship between LCs and mutational classes assigned in HMRN data with either the LymphGen,⁴⁶ or the HMRN classification (Figure 5b).⁵ These classifications though independently derived,^{4,5} are

largely concordant,⁴⁶ and recapitulate the features of the C1-C5 Harvard classification.² The 334 335 LymphGen MCD class was significantly associated with IcABC and IcABC-IR, while IcCT was 336 associated with cases with ambivalent MCD/ST2 calls. LymphGen N1 showed enrichment in 337 IcABC while BN2 was significantly and selectively associated with IcGCB-Xit. EZB was most 338 significantly enriched amongst IcGCB, IcGCB-DZ and GCB-FL, while EZB-MYC+ was selectively 339 enriched amongst _{lc}GCB-DZ. ST2 cases mapped selective on to _{lc}GCB-SOCS1. Similar patterns 340 of association were evident when considering the associations of LCs with the independent 341 but related HMRN mutational classification. We conclude that the mutation-based 342 subdivision of DLBCL in LymphGen and related classifications overlaps significantly with LCs 343 derived independently from gene co-expression patterns.

344

345 Lymphoma communities underline distinctions between double-hit lymphomas

346 In DLBCL the occurrence of double- or triple-hit with rearrangement of MYC and BCL2 347 (MYC BCL2 DH) or MYC and BCL6 (MYC BCL6 DH), or MYC, BCL2 and BCL6 (MYC BCL2 BCL6 TH) identifies high-risk disease.⁸⁻¹¹ The relationships of these 348 349 rearrangement-based categories to gene expression and mutation features is relatively clear-cut for MYC BCL2 DH, but remains less well-defined for MYC BCL6 DH.⁴⁷⁻⁴⁹ We 350 351 therefore tested the association of rearrangement status and LCs in the HMRN cohort. 352 _{Ic}GCB-DZ was highly enriched for MYC BCL2 DH and MYC BCL2 BCL6 TH cases (Figure 5b). 353 In contrast, a more modest enrichment of MYC BCL2 DH cases was evident in LGCB, while 354 IcGCB-FL was selectively enriched for BCL2 SH. IcGCB-Xit was selectively enriched for 355 MYC BCL6 DH and BCL6 SH status but was not associated with any combination of BCL2 356 rearrangement, while _{Ic}ABC was enriched for cases with MYC SH.

357 We further assessed whether the LCs were significantly associated with morphological 358 diagnosis, COO class and molecular high grade (MHG) or double-hit signature (DHITsig) status.^{14,15} Two communities, IcGCB-FL and to a lesser extent IcGCB-DZ were linked to 359 360 concurrent or previous diagnosis of underlying FL supporting a primary separation of 361 disease biology in transformed FL cases (Figure 5b). IcPBL was selectively enriched for 362 plasmablastic lymphoma morphological diagnosis, $_{lc}$ IR and $_{lc}$ IR-TET2 for T-cell histiocyte rich 363 large B-cell lymphoma and LGCB-SOCS1 for primary mediastinal large B-cell lymphoma. At 364 gene expression level the LC communities recovered appropriate enrichments of GCB, ABC 365 and unclassified cases. IcGCB-DZ was selectively enriched for cases designated as MHG and

cases that were DHITsig positive. Notably DHITsig differed from MHG in also showing
 significant enrichment amongst _{Ic}PBL. We conclude that the DLBCL LCs separate
 meaningfully in relation to underlying rearrangement status, morphological diagnosis,
 previous expression-based classifiers of high-risk disease and the presence of underlying FL.

370

371 Lymphoma communities have prognostic significance in R-CHOP treated cases

372 Given the fact that LCs segregate cases with common pathological features, we assessed 373 whether LCs showed significant and reproducible survival differences. We addressed this 374 across 6 datasets encompassing sufficient cases treated with R-CHOP chemoimmunotherapy.^{3,5, 13, 29, 36, 37} Across multiple datasets the DLBCL community structure 375 376 separated risk (Figure 6) albeit with variation evident between cohorts most notably for 377 _{lc}GCB-DZ and _{lc}CT. Most adverse risk, in terms of meta-HR across the 6 datasets, was 378 observed for assignment of cases to IcPBL, followed by IcABC-IR, IcGCB-Xit, IcABC and IcIR-379 TET2. Intermediate and variable risk was observed for IcCT and IcGCB-DZ. At the other end of 380 the spectrum particularly good risk was associated with LCGCB-FL, LCGCB-SOCS1, LCGCB and 381 IcGCB-EMT. We conclude that the refined break down of DLBCLs in the 12-fold LC structure 382 has potential utility to refine the separation of risk groups, while remaining aligned to the 383 concept of the COO differentiation state.

384

385 Lymphoma communities show distinct responses to RB-CHOP

386 The REMoDL-B trial recently reported on extended follow-up identifying a benefit for proteasome inhibitor bortezomib with R-CHOP in cases classified as ABC-DLBCL.⁵⁰ We were 387 therefore interested to test whether LCs could provide further insight into responses to RB-388 389 CHOP. For overall (OS) and progression-free (PFS) survival the LCs were significantly 390 separated overall in the R-CHOP arm of the trial. In the RB-CHOP arm the significance of 391 separation for the LCs declined for both OS (R-CHOP p=0.0013, RB-CHOP p=0.11) and PFS (R-392 CHOP p=0.002, RB-CHOP p=0.02) (Figure 7). While there are inherent limitations in *post hoc* 393 analysis and the impact of 12-fold classification on case numbers, we were interested to 394 further compare the response for R-CHOP and RB-CHOP arms of the trial for each LC 395 (Supplemental Figure 9 and 10). While some indication of improved responses for the RB-396 CHOP arm was evident, for example for IcPBL case that achieved a 90%+ OS in the RB-CHOP

397 treated arm (OS p=0.04, PFS p=0.014), surprisingly, no difference in outcome was observed

398 for $_{lc}ABC$ or $_{lc}ABC$ -IR between R-CHOP and RB-CHOP arms.

399

400 **Bortezomib response in ABC cases with variant expression features**

401 The absence of survival difference between the two arms of the trial for cases classified as 402 _{lc}ABC contrasted with the apparent benefit of RB-CHOP amongst cases classified as ABC-403 DLBCL using the trial classifier ($_{T}ABC$). We therefore examined the relative distribution of 404 TABC cases across the LC assignments in REMoDL-B (Figure 8A). Of the 249 TABC cases 120 405 were also assigned to $_{L}ABC$ and 47 were assigned to $_{L}ABC$ -IR (together 67% of $_{T}ABC$). These 406 intersects included cases with most characteristic ABC expression patterns and showed no 407 significant survival separation between RB-CHOP and R-CHOP arms of the trial. In contrast 408 there was a suggestion of benefit for RB-CHOP over R-CHOP in TABC cases assigned to other 409 LCs. Thus, we conclude that response to RB-CHOP rather than being associated with the 410 most typical of ABC expression patterns is instead associated with cases that combine some 411 ABC expression features with additional features that lead to other (non-ABC) assignments 412 in the LC structure.

413

414 Discussion

Heterogeneity is a dominant feature of DLBCL biology. This has led to partially intersecting taxonomies. The most widely accepted of these are classification based on *MYC* and *BCL2* rearrangement status, COO classification based on gene expression patterns, and the recent mutational classifications defined in the LymphGen, Harvard and HMRN classifications.¹⁻⁴ However, there remains uncertainty about the inter-relationships between rearrangement, expression and mutation-based classifications.

Here we have used a framework of consistent patterns of gene expression and an inclusive, correlation-centred approach to address these questions from a different perspective. Our analysis learned from 2,500 cases drawing on broadly representative contributions of the DLBCL research community and was tested in nearly 2,500 additional cases from recent studies.^{2,12,13,26-35} The network generated using PGCNA derives modules of co-expressed genes that reflect inherent features of DLBCL expression data and reinforces the central importance of the subdivision between ABC and GCB states. The analysis illustrates how individual genes relate to each other within this context. Exemplifying this, the original COO
classifier genes segregate discretely between the two primary modules linked to features of
B-cell lineage, and many of the classifier genes and those in alternate COO classifiers,
emerge as hub-nodes with high information content in the network.^{34, 38} The pattern of gene
correlation at network level, illustrates how for any module or neighbourhood closely
correlated genes could be selected to report similarly on the expression state.

434 When applying the network to expression-based classification, we have found that using 435 correlation patterns captured in the network structure to select genes which are then 436 collapsed into metagenes reflecting module- or neighbourhood-level expression features, as 437 opposed to selecting highly variant genes and using these at gene-level, adds significant 438 value to the reproducibility of classification. For DLBCL, while the prevailing models for COO 439 classification enhanced with assessments such as MHG/DHITsig status or host response features already provide significant value to identify subsets of disease, 14, 15, 22, 23, 34, 38, 44 our 440 441 analysis illustrates that the integration of network features can discriminate expression 442 patterns that are not captured in previous approaches. In terms of clinical practice, the LC 443 structure could potentially be developed for case-by-case application, but that has not been 444 the intent of the current study.

Our approach is distinct from and complimentary to other recent studies of DLBCL 445 446 expression biology such as the Ecotyper that highlight the importance of distinct patterns of host response in DLBCL biology.^{22,23} These concepts build from earlier work identifying 447 features of host response that are linked to good outcome.^{12,13} The importance of immune 448 and stromal response features is underlined by the contribution that the related network 449 450 modules make to distinguishing subsets of cases. An interesting example is the link between 451 specific patterns of the M3 ImmuneResponseMonocyteEnriched neighbourhoods and 452 mutations in TET2 and DNMT3A. Indeed, an association between COO unclassified DLBCL and *TET2* mutation enrichment has previously been identified,³ and our analysis extends this 453 454 to refine the subgroup of immune response-rich DLBCL with TET2 mutation association. 455 TET2 inactivation can contribute to lymphomagenesis in a B-lineage intrinsic fashion in 456 murine models. However, TET2 inactivation contributes as an early event in haematopoiesis in these models and mutations in TET2 shared between DLBCL and subsequent 457 myelodysplasia/leukaemia in individual patients have been reported.⁵¹⁻⁵³ Similar to *TET2*. 458 459 DNMT3A mutations are also common features of clonal haematopoiesis/clonal cytopenia of

460 undetermined significance.⁵⁴⁻⁵⁶ In angioimmunoblastic T-cell lymphoma *TET2* and *DNMT3A* 461 mutation have been identified as early events shared with both concurrent clonal 462 haematopoiesis and subsequent DLBCL or other haematological malignancy.⁵⁷ It will 463 therefore be interesting to establish to what extent the expression patterns of _{Ic}IR-TET2 464 identifies patients with DLBCL who have associated clonal haematopoiesis and whether the 465 mutations in such DLBCL derive exclusively from neoplastic B-cells, or potentially in some 466 cases from components of the host response.

467 We demonstrate that the network-based approach can facilitate the recognition of groups 468 of cases based on expression state that overlap with mutational classifications, 469 rearrangement status and the presence of underlying FL. In the context of cases with 470 underlying FL the cases separate between those with balanced GCB neighbourhood-level 471 expression patterns and excellent prognosis on R-CHOP treatment and those with a 472 dominant DZ-like expression profile with a poorer prognosis. The _{lc}GCB-DZ cases are also 473 enriched for high-risk features such as MYC and BCL2 rearrangement and MHG and DHITsig expression profiles.^{8,10,14,49,58} In contrast the good risk _{lc}GCB-FL category is significantly 474 475 enriched for STAT6 mutations including the Y419F hotspot which has been characterised as a distinctive feature of a subset of FL.^{41,59-62} The _{lc}GCB-FL category is in many ways 476 477 consistent with recent studies showing that DLBCL with concurrent or underlying FL at diagnosis is not necessarily associated with adverse prognosis.^{63,64} Together the LCGCB-DZ 478 479 and IcGCB-FL categories argue for divergent patterns of FL evolution that are distinguished 480 on the one hand by MYC rearrangement and related expression features for LCGCB-DZ and 481 on the other for _{lc}GCB-FL a link with underlying *STAT6* mutation.

The treatment landscape of DLBCL is rapidly evolving and introduction of polatuzumab 482 vedoitin targeting CD79b is changing frontline therapy.⁶⁵ However, it remains of interest to 483 484 explore refined separation of expression state in R-CHOP based trial data. Recently the longer-term follow-up in the REMoDL-B trial has been reported identifying a significant 485 survival benefit in the trial-classified ABC or MHG cases.⁵⁰ Our analysis demonstrates that 486 the apparent response to RB-CHOP in the ABC-DLBCL subset observed in the trial 487 488 classifications is not associated with the set of cases that are identified both by the trial and 489 the LC classification as ABC. This overlap includes cases with the most typical ABC 490 expression patterns. Instead, the response appears to reside in cases with variant features 491 related to host response or differentiation state. We acknowledge that the post hoc

subdivision of trial classified cases into multiple subgroups raises substantial caveats. However, a notable feature is that cases identified as plasmablastic (_{Ic}PBL) and treated with RB-CHOP in the REMoDL-B trial show a favourable outcome. This is notable because _{Ic}PBL cases in other case series have the worst outcome overall when treated with R-CHOP, which has until recently been widely used for such cases.⁶⁶ Our analysis of the REMoDL-B data supports the arguments put forward from other studies that bortezomib-containing regimens should be considered in DLBCL with plasmablastic features.⁶⁶⁻⁷⁰

We conclude that our network-based approach yields an encompassing map of DLBCL tumour biology and illustrates how data integration and network analysis can refine expression-based stratification of DLBCL. Our analysis supports the argument that such refined stratification is needed to accurately identify treatment responses even within existing molecular subtypes.

504

505 Methods

506 (See also Supplemental Methods)

507 Expression datasets

508 Thirteen expression datasets were used for PGCNA (GSE4475, GSE4732, GSE10846, GSE12195, GSE19246, GSE22470, GSE31312, GSE32918, GSE34171, GSE53786, GSE87371, 509 GSE98588, Monti).^{2,12,13,26-35} For validation 4 datasets were used: HMRN (GSE181063), NCI 510 511 (NCICCR-DLBCL), REMoDLB (GSE117556) and Reddy (EGAS00001002606), (Supplemental Table 1).^{3,5,13,29,36,37} For RNA-seg datasets (NCI, Reddy) count data was processed using 512 DESeg2 v1.22.2 with VST-normalised data used for analysis. Probes were re-annotated 513 514 (http://mygene.info) ambiguous mappings were manually assigned. Datasets were quantile 515 normalised (Python qnorm) and probe sets merged (median value for probe sets with 516 Pearson correlation ≥ 0.2 and maximum value for those with correlation < 0.2).

517

518 Network generation

519 Discovery datasets (GSE10846 split into CHOP/RCHOP-treated) were processed using 520 PGCNA2 (<u>https://github.com/medmaca/PGCNA/tree/master/PGCNA2</u>), retaining the top 521 70% most variant genes present in ≥50% of the datasets, carrying out 1000 Leidenalg 522 clusterings and selecting the best using Scaled cluster enrichment scores. The resulting

network contained 16,054 genes (44,730 edges) split into 28 modules (Supplemental Table
1). The network was visualised using Gephi (version 0.9.2), and interactive HTML5 web
visualisations exported using the sigma.js library. Interactive networks are at
https://mcare.link/DLBCL2.

527

528 Network analysis

529 Clustering samples

530 supplemental methods: Before clustering, we split each module into See 531 submodules/neighbourhoods and collapsed the genes within these to single values 532 The most informative genes/MEV/NEVs were selected using several (MEV/NEVs). 533 approaches, and used to cluster the DLBCL datasets using two different approaches 534 PGCNA/ConsensusClustering $(CC)^1$. We used cluster results to explore how recurrently 535 discoverable the DLBCL communities were, allowing the selection of the most informative 536 attributes for clustering. The best results for the HMRN dataset were combined between 537 PGCNA/CC to generate ensemble Lymphoma Communities (LC). These were used to train a 538 machine learning tool to recover the LCs in every dataset.

539

540 Neighbourhoods

Each of the 28 modules was sub-clustered to create neighbourhoods. The existing PGCNA edge file was split at the module level and then clustered 5,000 times using Leidenalg. The best clustering (based on modularity score) for each module was retained. Multiple different runs converged onto the same answer. The neighbourhoods are detailed in Extended Data Figure 3.

546

547 Module Expression Values and Lymphoma communities

548 Genes per module/neighbourhood were collapsed down to single values: within each 549 dataset, which vary in available genes, the genes per module/neighbourhood were ranked 550 by gene_strength (sum of genes edges/correlations within its module). Representative 551 genes were selected and converted into a MEV or NEV by:

552 1. Per module/neighbourhood select top 10 genes based on ranks.

553 2. Per gene, standardize (z-score) the quantile-normalized log₂ expression data.

554 3. Per sample (patient) calculate the median of the 10 z-scores to give a MEV/NEV.

555

556 Lymphoma Community machine learning tool

557 Clustering results for HMRN were merged by selecting significant overlaps (p-value <558 0.0001) that form a community in either CC/PGCNA containing > 5 samples (Supplemental 559 Figure 1 & Supplemental Methods). This generated a high confidence set of LCs (n=298) 560 that formed a training dataset (Figure 4b top) that was used to train a machine learning 561 (ML) tool to recover the LC in other datasets. The training dataset was split using the 562 python Scikit-learn test train split function, stratifying on the LC class label, to give class-563 balanced randomised training (n=238) and validation (n=60) datasets. The validation 564 dataset was set aside to test the final selected model. The training data was used to carry 565 out stratified 5-fold cross-validation across 7 different machine learning methods. In total 566 4,802 parameters were tested across the ML tools, scoring with the Matthews correlation 567 coefficient (MCC). The best 3 models, using their optimal parameters, were combined using 568 soft voting to give a model with mean MCC of 0.89 across the 5-folds. This model was then 569 tested on the unseen validation data (n=60) with MCC of 0.87. This final model, termed 570 ML LC, was retrained using all 298 training samples and was used for all subsequent 571 classifications, including the HMRN dataset (Figure 4b bottom).

572

573 Survival analysis

574 Right-censored survival data, where available, was analysed using Survival library for R. The 575 expression of each gene (as z-score) or the ML_LC *p*-value was used as a continuous variable 576 in a Cox Proportional Hazards model and the ML_LC community for a Kaplan-Meier 577 estimator (using merged survival data). Meta-analysis across datasets was conducted by 578 fitting a fixed-effect model to hazard ratios, weighted by dataset size.

579

580 Mutation analysis

Analysis was carried out for HMRN (188 genes/431 samples), REMoDLB (70 genes/400 samples) and Reddy (150 genes/624 samples) datasets. Mutations were converted to a binary matrix for downstream analysis. For each dataset the point-biserial correlations were calculated between all pairs of mutated gene and MEV/NEV. The resulting correlation *p*-

- 585 values were converted to z-scores (python stats.norm.ppf) to convey the ±correlation along
- 586 with its significance. Significance of overlap between mutations and LC was calculated using
- 587 hypergeometric testing within each dataset. To generate meta results MEV/Community
- 588 mutation analysis p-values were combined using the Stouffer's Z method.
- 589

590 Data Availability Statement

- 591 The underlying primary datasets are available at the indicated data source (see above under
- 592 Expression Datasets). All resulting gene correlation data, module and neighbourhood gene
- 593 lists, and signature/ontology enrichments are available at https://mcare.link/DLBCL2.
- 594

595 Code Availability Statement

- 596 The DLBCL LC classifier and networks are available at <u>https://mcare.link/DLBCL2</u>.
- 597 PGCNA is available at https://github.com/medmaca/PGCNA/tree/master/PGCNA2
- 598 All other code is available on request.
- 599

600 Acknowledgements

601 This work was supported by Cancer Research UK program grant (C7845/A17723 and 602 C7845/A29212) (M.C, G.D., D.W, and R.T). HMRN is supported by Cancer Research UK 603 program grant A29685 (D.P., S.C., A.S., E.R.). D.J.H. was supported by a fellowship from 604 Cancer Research UK (CRUK) (RCCFEL\100072) and received core funding from Wellcome 605 (203151/Z/16/Z) to the Wellcome-MRC Cambridge Stem Cell Institute and from the CRUK 606 Cambridge Centre (A25117). D.J.H is supported by the National Institute for Health and Care 607 Research (NIHR) Cambridge Biomedical Research Centre (BRC-1215-20014). R.T., G.D., E.R., 608 A.S., D.P., D.W. are supported by the National Institute for Health and Care Research Leeds 609 Biomedical Research Centre. The views expressed are those of the authors and not 610 necessarily those of the NIHR or the Department of Health and Social Care. For the purpose 611 of Open Access, the authors have applied a CC BY public copyright licence to any Author 612 Accepted Manuscript version arising from this submission.

614 **References**

- 615 1. Alizadeh, A.A., *et al.* Distinct types of diffuse large B-cell lymphoma identified by 616 gene expression profiling. *Nature* **403**, 503-511 (2000).
- 617 2. Chapuy, B., *et al.* Molecular subtypes of diffuse large B cell lymphoma are associated 618 with distinct pathogenic mechanisms and outcomes. *Nat Med* **24**, 679-690 (2018).
- 6193.Schmitz, R., et al. Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma. N620Engl J Med **378**, 1396-1407 (2018).
- Wright, G.W., et al. A Probabilistic Classification Tool for Genetic Subtypes of Diffuse
 Large B Cell Lymphoma with Therapeutic Implications. *Cancer Cell* 37, 551-568 e514
 (2020).
- 6245.Lacy, S.E., et al. Targeted sequencing in DLBCL, molecular subtypes, and outcomes: a625Haematological Malignancy Research Network report. Blood 135, 1759-1771 (2020).
- 626 6. Pedrosa, L., *et al.* Proposal and validation of a method to classify genetic subtypes of 627 diffuse large B cell lymphoma. *Sci Rep* **11**, 1886 (2021).
- 628 7. Bolen, C.R., et al. Prognostic impact of somatic mutations in diffuse large B-cell
 629 lymphoma and relationship to cell-of-origin: data from the phase III GOYA study.
 630 Haematologica 105, 2298-2307 (2020).
- Aukema, S.M., *et al.* Biological characterization of adult MYC-translocation-positive
 mature B-cell lymphomas other than molecular Burkitt lymphoma. *Haematologica*99, 726-735 (2014).
- 634 9. Aukema, S.M., *et al*. Double-hit B-cell lymphomas. *Blood* **117**, 2319-2331 (2011).
- 63510.Barrans, S., et al. Rearrangement of MYC is associated with poor prognosis in636patients with diffuse large B-cell lymphoma treated in the era of rituximab. J Clin637Oncol 28, 3360-3365 (2010).
- Li, S., et al. B-cell lymphomas with MYC/8q24 rearrangements and
 IGH@BCL2/t(14;18)(q32;q21): an aggressive disease with heterogeneous histology,
 germinal center B-cell immunophenotype and poor outcome. *Mod Pathol* 25, 145156 (2012).
- Monti, S., et al. Molecular profiling of diffuse large B-cell lymphoma identifies robust
 subtypes including one characterized by host inflammatory response. *Blood* 105,
 1851-1861 (2005).
- Lenz, G., et al. Stromal gene signatures in large-B-cell lymphomas. The New England *journal of medicine* 359, 2313-2323 (2008).
- 64714.Sha, C., et al. Molecular High-Grade B-Cell Lymphoma: Defining a Poor-Risk Group648That Requires Different Approaches to Therapy. J Clin Oncol 37, 202-212 (2019).
- 64915.Ennishi, D., et al. Double-Hit Gene Expression Signature Defines a Distinct Subgroup650of Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma. J Clin Oncol 37, 190-651201 (2019).
- 65216.Holmes, A.B., et al. Single-cell analysis of germinal-center B cells informs on653lymphoma cell of origin and outcome. J Exp Med 217(2020).
- 65417.King, H.W., et al. Single-cell analysis of human B cell maturation predicts how655antibody class switching shapes selection dynamics. Sci Immunol 6(2021).
- 656 18. Milpied, P., *et al.* Human germinal center transcriptional programs are de-657 synchronized in B cell lymphoma. *Nat Immunol* **19**, 1013-1024 (2018).
- Attaf, N., Baaklini, S., Binet, L. & Milpied, P. Heterogeneity of germinal center B cells:
 New insights from single-cell studies. *Eur J Immunol* 51, 2555-2567 (2021).

660	20.	Duan, L., et al. Follicular dendritic cells restrict interleukin-4 availability in germinal
661		centers and foster memory B cell generation. <i>Immunity</i> 54, 2256-2272 e2256 (2021).
662	21.	Kennedy, D.E., et al. Novel specialized cell state and spatial compartments within the
663		germinal center. <i>Nat Immunol</i> 21 , 660-670 (2020).
664	22.	Steen, C.B., et al. The landscape of tumor cell states and ecosystems in diffuse large
665		B cell lymphoma. <i>Cancer Cell</i> 39 , 1422-1437 e1410 (2021).
666	23.	Kotlov, N., et al. Clinical and Biological Subtypes of B-cell Lymphoma Revealed by
667		Microenvironmental Signatures. <i>Cancer discover</i> y 11 , 1468-1489 (2021).
668	24.	Care, M.A., Westhead, D.R. & Tooze, R.M. Parsimonious Gene Correlation Network
669		Analysis (PGCNA): a tool to define modular gene co-expression for refined molecular
670		stratification in cancer. NPJ Syst Biol Appl 5, 13 (2019).
671	25.	Stephenson, S., et al. Growth Factor-like Gene Regulation Is Separable from Survival
672		and Maturation in Antibody-Secreting Cells. <i>J Immunol</i> 202 , 1287-1300 (2019).
673	26.	Compagno, M., et al. Mutations of multiple genes cause deregulation of NF-kappaB
674		in diffuse large B-cell lymphoma. <i>Nature</i> 459 , 717-721 (2009).
675	27.	Williams, P.M., et al. A novel method of amplification of FFPET-derived RNA enables
676		accurate disease classification with microarrays. <i>J Mol Diagn</i> 12 , 680-686 (2010).
677	28.	Salaverria, I., et al. Translocations activating IRF4 identify a subtype of germinal
678		center-derived B-cell lymphoma affecting predominantly children and young adults.
679	• •	Blood 118 , 139-147 (2011).
680	29.	Frei, E., et al. Addition of rituximab to chemotherapy overcomes the negative
681		prognostic impact of cyclin E expression in diffuse large B-cell lymphoma. J Clin
682	20	Pathol 66, 956-961 (2013).
683	30.	Care, M.A., et al. SPIB and BATF provide alternate determinants of IRF4 occupancy in
684 685		diffuse large B-cell lymphoma linked to disease neterogeneity. <i>Nucleic Acids Res</i> 42,
685	24	7591-7610 (2014).
607	51.	nottern of nE2 and call cycle deregylation in diffuse large R call lymphoma. Cancer
600		
680	30	Hummal M et al. A biologic definition of Burkitt's lymphoma from transcriptional
690	52.	and genemic profiling. The New England journal of medicine 354 , 2419, 2430 (2006)
691	22	Dave SS et al Molecular diagnosis of Burkitt's lymphoma. The New England
692	55.	journal of medicine 354 2/31-2/42 (2006)
693	34	Scott DW et al Determining cell-of-origin subtynes of diffuse large B-cell
694	54.	lymphoma using gene expression in formalin-fixed naraffin-embedded tissue <i>Blood</i>
695		123 . 1214-1217 (2014).
696	35	Dubois S et al Biological and Clinical Relevance of Associated Genomic Alterations
697		in MYD88 L265P and non-L265P-Mutated Diffuse Large B-Cell Lymphoma: Analysis of
698		361 Cases. <i>Clin Cancer Res</i> 23 . 2232-2244 (2017).
699	36.	Reddy, A., et al. Genetic and Functional Drivers of Diffuse Large B Cell Lymphoma.
700		<i>Cell</i> 171 , 481-494 e415 (2017).
701	37.	Davies, A., et al. Gene-expression profiling of bortezomib added to standard
702		chemoimmunotherapy for diffuse large B-cell lymphoma (REMoDL-B): an open-label,
703		randomised, phase 3 trial. Lancet Oncol 20, 649-662 (2019).
704	38.	Wright, G., et al. A gene expression-based method to diagnose clinically distinct
705		subgroups of diffuse large B cell lymphoma. Proc Natl Acad Sci U S A 100, 9991-9996
706		(2003).

707	39.	Basso, K. & Dalla-Favera, R. Germinal centres and B cell lymphomagenesis. Nat Rev
708		Immunol 15 , 172-184 (2015).
709	40.	Shaffer, A.L., 3rd, Young, R.M. & Staudt, L.M. Pathogenesis of human B cell
710		lymphomas. <i>Annual review of immunology</i> 30 , 565-610 (2012).
711	41.	Crouch, S., et al. Molecular subclusters of follicular lymphoma: a report from the
712		United Kingdom's Haematological Malignancy Research Network. Blood Adv 6, 5716-
713		5731 (2022).
714	42.	Ennishi, D., et al. TMEM30A loss-of-function mutations drive lymphomagenesis and
715		confer therapeutically exploitable vulnerability in B-cell lymphoma. Nat Med 26 , 577-
716		588 (2020).
717	43.	Wilkerson, M.D. & Hayes, D.N. ConsensusClusterPlus: a class discovery tool with
718		confidence assessments and item tracking. <i>Bioinformatics</i> 26 , 1572-1573 (2010).
719	44.	Care, M.A., et al. A Microarray Platform-Independent Classification Tool for Cell of
720		Origin Class Allows Comparative Analysis of Gene Expression in Diffuse Large B-cell
721		Ivmnhoma PLoS ONE 8 e55895 (2013)
722	45	Swift S et al Consensus clustering and functional interpretation of gene-expression
723	10.	data Genome biology 5 R94 (2004)
724	46	Runge HEP et al. Application of the LymphGen classification tool to 928 clinically
724	40.	and genetically characterised cases of diffuse large R cell lymphoma (DIRCI) Br /
725		Happenetel (2020)
720	47	Recentration (2020).
727	47.	Translanction Dertain in Diffuse Lange D. Cell Lung have a Chudu by the Lung have
728		ransiocation Partner in Diffuse Large B-Cell Lymphoma: A Study by the Lunenburg
729		Lymphoma Biomarker Consortium. J Clin Oncol 37 , 3359-3368 (2019).
/30	48.	Cucco, F., et al. Distinct genetic changes reveal evolutionary history and
731		heterogeneous molecular grade of DLBCL with MYC/BCL2 double-hit. <i>Leukemia</i> 34,
732		1329-1341 (2020).
733	49.	Scott, D.W., et al. High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6
734		rearrangements with diffuse large B-cell lymphoma morphology. <i>Blood</i> 131 , 2060-
735		2064 (2018).
736	50.	Davies, A.J., et al. Differential Efficacy From the Addition of Bortezomib to R-CHOP in
737		Diffuse Large B-Cell Lymphoma According to the Molecular Subgroup in the
738		REMoDL-B Study With a 5-Year Follow-Up. <i>J Clin Oncol</i> , JCO2300033 (2023).
739	51.	Quivoron, C., et al. TET2 inactivation results in pleiotropic hematopoietic
740		abnormalities in mouse and is a recurrent event during human lymphomagenesis.
741		Cancer Cell 20 , 25-38 (2011).
742	52.	Dominguez, P.M., et al. TET2 Deficiency Causes Germinal Center Hyperplasia, Impairs
743		Plasma Cell Differentiation, and Promotes B-cell Lymphomagenesis. <i>Cancer discovery</i>
744		8 , 1632-1653 (2018).
745	53.	Mouly, E., et al. B-cell tumor development in Tet2-deficient mice. Blood Adv 2, 703-
746		714 (2018).
747	54.	Edwards, J.P., Thornton, A.M. & Shevach, F.M. Release of active TGE-beta1 from the
748	•	latent TGE-beta1/GARP complex on T regulatory cells is mediated by integrin beta8.
749		Immunol 193 2843-2849 (2014)
750	55	Genovese G et al Clonal hematonoiesis and blood-cancer risk inferred from blood
751	55.	DNA sequence N Engl Med 371 2/177-2/187 (2014)
757	56	laiswal S at al Age-related clonal homotopoissic associated with adverse
752	50.	outcomes N Engl I Med 371 2/88-2/98 (2014)
, , , ,		Outcomes

- 754 57. Cheng, S., Zhang, W., Inghirami, G. & Tam, W. Mutation analysis links
 755 angioimmunoblastic T-cell lymphoma to clonal hematopoiesis and smoking. *eLife*756 **10**(2021).
- 75758.Marshall, H.D., et al. The transforming growth factor beta signaling pathway is758critical for the formation of CD4 T follicular helper cells and isotype-switched759antibody responses in the lung mucosa. eLife 4, e04851 (2015).
- Yildiz, M., et al. Activating STAT6 mutations in follicular lymphoma. Blood 125, 668679 (2015).
- 50. Siddiqi, I.N., *et al.* Characterization of a variant of t(14;18) negative nodal diffuse
 follicular lymphoma with CD23 expression, 1p36/TNFRSF14 abnormalities, and
 STAT6 mutations. *Mod Pathol* 29, 570-581 (2016).
- 76561.Xian, R.R., et al. CREBBP and STAT6 co-mutation and 16p13 and 1p36 loss define the766t(14;18)-negative diffuse variant of follicular lymphoma. Blood Cancer J 10, 69767(2020).
- Mentz, M., et al. PARP14 is a novel target in STAT6 mutant follicular lymphoma. *Leukemia* 36, 2281-2292 (2022).
- Behdad, A., et al. Survival outcomes of diffuse large B-cell lymphoma by association
 with concurrent or antecedent follicular lymphoma and double hit status. Leuk
 Lymphoma 60, 3266-3271 (2019).
- 77364.Wang, Y., et al. Impact of concurrent indolent lymphoma on the clinical outcome of774newly diagnosed diffuse large B-cell lymphoma. Blood 134, 1289-1297 (2019).
- 775 65. Tilly, H., et al. Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell
 776 Lymphoma. N Engl J Med 386, 351-363 (2022).
- Makady, N.F., Ramzy, D., Ghaly, R., Abdel-Malek, R.R. & Shohdy, K.S. The Emerging
 Treatment Options of Plasmablastic Lymphoma: Analysis of 173 Individual Patient
 Outcomes. *Clin Lymphoma Myeloma Leuk* 21, e255-e263 (2021).
- Guerrero-Garcia, T.A., Mogollon, R.J. & Castillo, J.J. Bortezomib in plasmablastic
 lymphoma: A glimpse of hope for a hard-to-treat disease. *Leuk Res* 62, 12-16 (2017).
- Dittus, C., Grover, N., Ellsworth, S., Tan, X. & Park, S.I. Bortezomib in combination
 with dose-adjusted EPOCH (etoposide, prednisone, vincristine, cyclophosphamide,
 and doxorubicin) induces long-term survival in patients with plasmablastic
 lymphoma: a retrospective analysis. *Leuk Lymphoma* 59, 2121-2127 (2018).
- 69. Castillo, J.J., *et al.* Bortezomib plus EPOCH is effective as frontline treatment in patients with plasmablastic lymphoma. *Br J Haematol* 184, 679-682 (2019).
- 70. Sabry, W., Wu, Y. & Kodad, S.G. Bortezomib, Lenalidomide and Dexamethasone
 Combination Induced Complete Remission in Relapsed/Refractory Plasmablastic
 Lymphoma: Case Report of a Potential Novel Treatment Approach. *Curr Oncol* 29,
 5042-5053 (2022).
- 792



M15 Ribosome M25 M8 Mitochondrian MYC_Overexpression Module RibosomeBiogenes M17 Chr17p M10 ImmuneResponse M20 E2F_EGFR uneResponse Imm M9 GCB M24 ChrY o IFN M11 ABC SterolBiosynthe M6 Zinc-Finger egulationOfTranscription CommonCancerGenes M2 DIDO1_Targets Mitochondria

Meta Hazard Ratio 1.25 1.50 M1 M12 M19 7 M5 M2 M6 M28 M18 M23 M20 M21 M13 M10 М3 M26 M22 M4 M9

T-Cell

IFN

Y. Metalthiolate

ABC

GCB

MHC II

MARCA2 Targets

GF-TNF NRG1

Chr 17p

Cell-Cycle

Nucleosom

Figure 1. PGCNA network visualization for DLBCL

M19

(a) DLBCL network with modules colour-coded, modules outlines are approximated with ellipses of same colour with module summary term indicated. Interactive versions are available at https://mcare.link/DLBCL for detailed exploration. (b) Separation of module signature and ontology associations is illustrated as a heatmap (filtered FDR <0.05 and ≥ 5 and ≤ 1000 genes; top 15 most significant signatures per module). Significant enrichment or depletion illustrated on red/blue scale, x-axis (modules) and y-axis (signatures). Hierarchical clustering according to gene signature enrichment. For high-resolution version and extended data see Extended Data Figure 2 and Supplemental Table 2. (c) Overlay of meta-hazard ratio (HR) of death across available meta-data in training datasets. Corresponding module outline approximations are illustrated as in (a). Colour scales: outcome blue (low HR - good outcome) to red (high HR - poor outcome). Interactive version available at https://mcare.link/DLBCL for detailed exploration, along with additional meta-data overlays. (d) Ranked module level association with HR of death. Distribution of HR associations for module genes with p-value < 0.05, along with median (blue square) and IQR.



Figure 2. GCB and ABC module neighbourhoods provide fine-grained resolution

(a) Modules M9_GCB (blue) and M11_ABC (yellow) are displayed as a merged ABC/GCB specific network with node sizes reflecting degree. (b) The ABC/GCB specific network structure as in (a) colour coded according to gene neighbourhood membership, with colour key provided to the right. (c) and (d) Separation of neighbourhood signature and ontology associations are illustrated as a bubble plot for M9_GCB (c) and M11_ABC (d) (showing select signatures). Significant enrichment illustrated by colour and bubble size, x-axis (neighbourhoods) and y-axis (signatures) for relevant signatures. For high-resolution version and extended data see Extended Data Figure 3 and Supplemental Table 4.



Figure 3. Relationship between MEV/NEVs and mutations

Association of Module/Neighbourhood Expression Values (MEV/NEV) with mutations. Shown are combined significance (Stouffer method) of p-value based on point-biserial correlations between binary mutation status and MEV/NEVs across 3 datasets (HMRN, Reddy & REMoDLB). Only mutations with p-value < 0.001, occurring in \geq 2 datasets were retained, Z-scores for p-values > 0.001 were set to 0. Significance is shown as z-scores on a blue (significant depletion) to red (significant enrichment) scale (-5 to +5). Centre shows the relationship between MEVs and mutations. Outside shows the relationship between select NEVs and mutations.



The attributes used for clustering samples were tested using a machine learning (ML) approach (see EDF1) that assessed the recurrence of discovered clusters between clusterings of different DLBCL datasets. (a) displays violin plots of Z-scores showing the significance of cluster recurrence based on overlaps between clusters in different DLBCL datasets (comparing unsupervised/supervised clusterings between each pair of datasets (n=16), yielding 240 comparisons (per K level); see EDF1, ST5 and Supplemental Methods). Attributes were clustered using CC (linkage:average and method: HC/PAM) or with PGCNA. The bars at the top show the level - gene or collapsed to MEV/NEV and the attribute type - Top1000: top 1000 genes with highest median absolute deviation, Network: most variant genes per neighbourhood (SelectG_MADS), Net+Strct: most variant neighbourhoods (genes per neighbourhood selected based on network edge strength; SelectG_NEV-MADM) and Net+Strct/NEV_M9M11: most variant modules/neighbourhoods (genes per module/neighbourhood selected based on network edge strength; SelectG_NEV-MADM) with only modules M9 and M11 at the neighbourhood level. Violin plots show the median (solid line) and Q1/Q3 (dotted lines) along with each comparison (white dot, n=240) for the k=12 CC results. The horizontal black line is set at the highest median value. (b) using the most informative attribute set (MEV/NEV NEV_M9M11; n=41 MEV/NEV) the overlapping CC_K12 and PGCNA clusterings of the HMRN dataset formed a training dataset to build a ML classifier. The top heatmap shows the training data and the bottom shows the total HMRN dataset reclassified using the trained ML tool (ML_LC). Each row shows the expression of the displayed MEV/NEV across the samples on a blue (low) to red (high) z-score colour scale. (c) the fraction of each LC across the datasets classified using ML_LC.



b

Figure 5. Lymphoma Communities (LC) have distinct mutational and rearrangement associations.

Association of LC with mutation and rearrangement status. (a) The differential enrichment of gene mutations across LC integrated across three datasets. Shown is combined significance (Stouffer method) of LC enrichment/depletion of mutations as z-scores on a blue (significant depletion) to red (significant enrichment) scale (-5 to +5). X-axis shows hierarchically clustered LC and y-axis gene symbols. Only mutations with p-value < 0.01, occurring in \geq 2 datasets were retained, Z-scores for p-values > 0.01 were set to 0. (b) Significance of enrichment/depletion of LC with LymphGen, HMRN mutational group (PMID: 32187361), Hit-status (rearrangement status for MYC, BCL2 and BCL6 indicating single hit (SH), double hit MYC_B-CL2-DH or MYC_BCL6-DH, or triple hit MYC_BCL2_BCL6-TH), Diagnostic-Group, cell-of-origin/MHG and DHITsig assignments in the HMRN dataset. X-axis hierarchically clustered LC, against y-axis clustered within each group. Z-scores with p-value > 0.05 were set to 0.





Figure 6. Lymphoma communities are significantly associated with overall survival

b

(a) Lymphoma Communities (LC) across the indicated datasets show consistent associations for hazard ratio (HR) of overall survival for R-CHOP treated patients. Heatmaps shows HR on a blue (good) to red (poor) colour scale across 6 datasets ordered by metaHR (from Cox proportional hazards regression; ML_LC LC p-value as the explanatory variable). The left chart shows the median fraction size of each LC across the 6 datasets. The right charts show the Log10 MetaHR (red) and -Log10 p-value (grey) with p<0.05 indicated by a dashed-line. (b) Kaplan-Meier plots of overall survival for R-CHOP treated patients across the 6 DLBCL datasets for shown LC; p-value from log-rank test.



Figure 7. IcPBL and IcCT show improved survival with addition of bortezomib

Shows Kaplan-Meier plots of survival for the indicated Lymphoma Communities (LC) within the REMoDLB dataset split by treatment (R-CHOP or with addition of bortezomib; RB-CHOP) and survival (overall-survival:OS, progression-free-survival:PFS). (a) R-CHOP OS, (b) R-CHOP PFS, (c) RB-CHOP OS and (d) RB-CHOP PFS. P-value from log-rank test.

medRxiv preprint (which was not	IcAB	IcABC-	lcGCB-Xit	101/2022 w) is the made a		2227533 funder, v under a	IcIR-T	ICGCB-	Dested Ju med Rxi mationa OSO	IcGCB State St	IcGO BC S S S S S S S S S S S S S S S S S S	lcGCB-SOCS1	holder fo	r this preprint n perpetuity.
, <mark>_ABC</mark>	120	47	6	14	7	35	16	0	1	1	0	2	249	
_⊤ GCB	30	4	18	11	6	48	22	38	40	72	87	92	468	
_т МНG	2	0	5	0	7	0	1	0	0	49	16	3	83	
	12	2	1	2	3	55	43	5	1	1	1	2	128	
Total	164	53	30	27	23	138	82	43	42	123	104	99	928	



Figure 8. High confidence ABC does not show significant survival advantage with addition of bortezomib

(a) shows the overlap between REMoDLB trial COO assignments (rows) and Lymphoma Communities (columns). The samples used in part b have a black border. (b) Shows Kaplan-Meier plots of survival for Lymphoma Community overlap subsets of the TABC group. Each plot compares the treatments: R-CHOP (lighter-line) and RB-CHOP (darker-line) with overall-survival (top row) and progression-free-survival (bottom row). P-value from log-rank test.